Clinical Trials & Patents

Clinical Trials

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension The trial is completed and does not include any patients.

Rationale: Mutations in bone morphogenetic protein receptor 2 (BMPR2) are present in >80% of familial and ~20% of sporadic pulmonary arterial hypertension (PAH) patients. Furthermore dysfunctional BMP signaling is a general feature of pulmonary hypertension even in non-familial PAH.

We have discovered that FK506 increases BMPR2 signaling and reverses experimental pulmonary hypertension.    
Identifier: NCT01647945


“United States Patent 61481317 Low dose FK506 for the treatment of Pulmonary Arterial Hypertension”

Leland Stanford Junior University

Phil Beachy, PhD
David Solow-Cordero, PhD
Marlene Rabinovitch, MD
Edda Spiekerkoetter, MD